StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
AbbVie (ABBV) Reports New Data from Phase 3 MURANO Trial of VENCLEXTA/VENCLYXTO (venetoclax) in Combination with Rituximab
December 3, 2018 6:10 AM
AbbVie (NYSE: ABBV) presented updated data from the pivotal Phase 3 MURANO trial of venetoclax (VENCLEXTA® or VENCLYXTO®) in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed
December 1, 2018 5:47 PM
Pfizer (PFE) Reaches Global Agreement with AbbVie (ABBV) on Adalimumab Biosimilar
November 30, 2018 10:01 AM